期刊
HUMAN GENE THERAPY
卷 21, 期 11, 页码 1513-1526出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2010.165
关键词
-
资金
- National Heart, Lung, and Blood Institute [RO1 HL35610, HL81744, HL72010, HL73219]
- Edna Mandel Foundation
- Leducq Foundation
- American Heart Association [10SDG4280011]
The use of stem cells for tissue regeneration and repair is advancing both at the bench and bedside. Stem cells isolated from bone marrow are currently being tested for their therapeutic potential in a variety of clinical conditions including cardiovascular injury, kidney failure, cancer, and neurological and bone disorders. Despite the advantages, stem cell therapy is still limited by low survival, engraftment, and homing to damage area as well as inefficiencies in differentiating into fully functional tissues. Genetic engineering of mesenchymal stem cells is being explored as a means to circumvent some of these problems. This review presents the current understanding of the use of genetically engineered mesenchymal stem cells in human disease therapy with emphasis on genetic modifications aimed to improve survival, homing, angiogenesis, and heart function after myocardial infarction. Advancements in other disease areas are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据